Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-7838
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron ; volume:32 ; number:9 ; day:29 ; month:7 ; year:2022 ; pages:831-842 ; date:9.2022
Cell research ; 32, Heft 9 (29.7.2022), 831-842, 9.2022
- Creator
-
Ma, Huan
Zhang, Xinghai
Zheng, Peiyi
Dube, Peter H.
Zeng, Weihong
Chen, Shaohong
Cheng, Qingyu
Yang, Yunru
Wu, Yan
Zhou, Junhui
Hu, Xiaowen
Xiang, Yan
Zhang, Huajun
Chiu, Sandra
Jin, Tengchuan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41422-022-00700-3
- URN
-
urn:nbn:de:101:1-2022111909160934925536
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ma, Huan
- Zhang, Xinghai
- Zheng, Peiyi
- Dube, Peter H.
- Zeng, Weihong
- Chen, Shaohong
- Cheng, Qingyu
- Yang, Yunru
- Wu, Yan
- Zhou, Junhui
- Hu, Xiaowen
- Xiang, Yan
- Zhang, Huajun
- Chiu, Sandra
- Jin, Tengchuan
- SpringerLink (Online service)
Other Objects (12)
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
Applying unconventional secretion for the export of bivalent Sars-CoV2 nanobodies in Ustilago maydis
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Monovalent, bivalent and biparatopic nanobodies targeting S1 protein of porcine epidemic diarrhea virus efficiently neutralized the virus infectivity
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
Applying unconventional secretion for the export of bivalent Sars-CoV2 nanobodies in Ustilago maydis
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Monovalent, bivalent and biparatopic nanobodies targeting S1 protein of porcine epidemic diarrhea virus efficiently neutralized the virus infectivity
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
Applying unconventional secretion for the export of bivalent Sars-CoV2 nanobodies in Ustilago maydis
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Monovalent, bivalent and biparatopic nanobodies targeting S1 protein of porcine epidemic diarrhea virus efficiently neutralized the virus infectivity
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients